HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of the diverse variants of HIV. Neutralizing antibodies are proteins produced by the immune system that bind to and block the activity of viruses, bacteria, or other pathogens.
Dual studies reveal early successes for mRNA HIV vaccine strategies
